Estrogen receptor (ER)-negative
cancers have a poor prognosis, and few targeted
therapies are available for their treatment. Our previous analyses have identified potential
kinase targets critical for the growth of ER-negative,
progesterone receptor (PR)-negative and HER2-negative, or "
triple-negative" breast cancer (TNBC). Because
phosphatases regulate the function of
kinase signaling pathways, in this study, we investigated whether
phosphatases are also differentially expressed in ER-negative compared to those in ER-positive breast
cancers. We compared
RNA expression in 98 human breast
cancers (56 ER-positive and 42 ER-negative) to identify
phosphatases differentially expressed in ER-negative compared to those in ER-positive breast
cancers. We then examined the effects of one selected
phosphatase, dual specificity phosphatase 4 (DUSP4), on proliferation, cell growth, migration and invasion, and on signaling pathways using
protein microarray analyses of 172
proteins, including
phosphoproteins. We identified 48
phosphatase genes are significantly differentially expressed in ER-negative compared to those in ER-positive
breast tumors. We discovered that 31
phosphatases were more highly expressed, while 11 were underexpressed specifically in ER-negative breast
cancers. The DUSP4 gene is underexpressed in ER-negative
breast cancer and is deleted in approximately 50 % of breast
cancers. Induced DUSP4 expression suppresses both in vitro and in vivo growths of
breast cancer cells. Our studies show that induced DUSP4 expression blocks the cell cycle at the G1/S checkpoint; inhibits ERK1/2, p38, JNK1, RB, and NFkB p65 phosphorylation; and inhibits invasiveness of TNBC cells. These results suggest that that DUSP4 is a critical regulator of the growth and invasion of
triple-negative breast cancer cells.